Parkinson's Foundation PD GENEration Genetic Registry
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04994015 |
Recruitment Status :
Recruiting
First Posted : August 6, 2021
Last Update Posted : May 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Parkinson's Disease | Device: Lab Assay for seven genetic variants for Parkinson's Disease |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 25000 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Target Follow-Up Duration: | 30 Days |
Official Title: | Parkinson's Foundation PD GENEration Genetic Registry |
Actual Study Start Date : | December 20, 2020 |
Estimated Primary Completion Date : | December 31, 2024 |
Estimated Study Completion Date : | June 1, 2025 |
- Device: Lab Assay for seven genetic variants for Parkinson's Disease
Counseling provided to participant by site clinician/physician/genetic counselor.
- Prevalence of Parkinson's related genetic mutations in an convenience cohort [ Time Frame: 6 months ]Identify people with Parkinson's who have genetic mutations to advance basic science and clinical research.
- Educating people with Parkinson's of their genetic mutation status through genetic testing and counseling [ Time Frame: 6 months ]People who are informed of their genetic status may be empowered to learn more about their disease and participant in clinical research.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
Study Population 1: PWP (open for recruitment)
- Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
- Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
- Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
- Able to perform study activities (including completion of either online, in-person or paper surveys).
Study Population 2: People at risk of developing PD (not open for recruitment)
1. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.
Exclusion Criteria:
- Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
- Individuals who have received a blood transfusion within the past 3 months.
- Individuals who have active hematologic malignancies such as lymphoma or leukemia.
- Individuals who have had a bone marrow transplant within the past 5 years.
- Under the age of 18
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04994015
Contact: Kamalini Ghosh, MS | 1-800-473-4636 | kghosh@parkinson.org |
Principal Investigator: | James Beck, PhD | Parkinson's Foundation | |
Principal Investigator: | Roy N Alcalay, MS, MD | Tel Aviv Sourasky Medical Center, Columbia University Irving Medical Center |
Responsible Party: | Parkinson's Foundation |
ClinicalTrials.gov Identifier: | NCT04994015 |
Other Study ID Numbers: |
PDGENE-PF |
First Posted: | August 6, 2021 Key Record Dates |
Last Update Posted: | May 7, 2024 |
Last Verified: | May 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Genetics Genetic Counseling Whole Genome Sequencing |
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |